Peripheral artery disease assessment typically focuses on the evaluation of lower extremity symptoms and physical findings. Few practitioners consider the importance of upper extremity arterial disease; which, besides causing hand and arm symptoms, can be associated with significant neurologic and cardiac sequelae. A review of the existing literature through PubMed using the search term 'subclavian stenosis' was performed. The latest original articles, including clinical studies, case reports and limited reviews of this topic were adapted. A comprehensive article review focusing on the diagnostic and treatment approach for subclavian stenosis was prepared. In conclusion, vascular medicine practitioners including cardiologists and vascular surgeons caring for patients with arterial disease should routinely assess for subclavian stenosis. There are excellent screening tools and effective medical therapies which can be instituted if diagnosed early. When the need for revascularization arises, percutaneous modalities are favored given their proven long-term efficacy, decreased morbidity and mortality, and cost-effectiveness.
Background
Subclavian artery stenosis can be a cause of significant morbidity as it can lead to symptomatic ischemic issues affecting the upper extremities, brain and in some cases the heart. Atherosclerosis is the most common cause of this condition, but other etiologies include arteritis, inflammation due to radiation exposure, compression syndromes, fibromuscular dysplasia, and neurofibromatosis. The incidence of subclavian stenosis in the general population ranges from 3% to 4%, 1 and can be as high as 11-18% in patients with documented peripheral artery disease. 2 Of those patients found to have subclavian or innominate lesions, 50% have concomitant coronary artery disease, 27% lower extremity artery involvement and 29% carotid obstructive disease. 3, 4 As a result, patients affected with this disease are at increased risk of developing symptomatic coronary artery disease and cerebrovascular events. [5] [6] [7] The left subclavian artery is four times more likely to be affected than the right or innominate arteries. 3, 8, 9 If there is an isolated stenosis, due to the degree of potential collateralization, the likelihood of symptoms is less than in other vascular beds. However, once obstructive disease affects other aortic arch vessels, namely the carotid or vertebral arteries, the likelihood of steal or ischemic symptoms drastically increases. Upper extremity symptoms can include arm claudication or muscle fatigue, rest pain and finger necrosis from embolic debris. Neurologic issues are typically characterized by vertebrobasilar hypoperfusion including visual disturbances, syncope, ataxia, vertigo, dysphasia, dysarthria and facial sensory deficits. In patients with internal mammary artery (IMA) grafts as a result of coronary artery bypass graft (CABG) surgery, the symptoms of ischemic heart disease, including angina pectoris, due to coronary-subclavian steal, predominate.
Diagnosis

Physical examination
While the definitive diagnosis typically rests on imaging, the importance of a thorough physical exam must be underscored. On exam, patients can display unequal arm blood pressures, absent or significantly diminished pulses (axillary, brachial and radial/ulnar) in comparison to the contralateral arm, and cervical or supraclavicular bruits. In addition, ischemic findings such as finger ulcers or gangrenous skin changes and nail bed splinter hemorrhages can be seen. Examination should also focus on the cerebral circulation including palpation of carotid pulses as well as auscultation for vertebral (suboccipital region) and carotid bruits. In an observational study by English et al., 1 non-invasive blood pressure measurements of 492 patients undergoing cardiac catheterization, with confirmation using invasive measures such as angiography and intra-arterial pressure gradients, found a 99% negative predictive value using a systolic blood pressure difference cut-off of > 10 mmHg (with a positive predictive value of 13%). Similar studies with much fewer subjects but using a systolic cut-off of 15 and 20 mmHg found positive predictive values of 100% and 67%, respectively, both with 100% negative predictive values. 10, 11 As such, a systolic cuff pressure difference or gradient (in the case of invasive assessment) of > 10 mmHg can be used to delineate hemodynamic significance and justify further investigation.
Diagnostic imaging
Once a significant blood pressure difference is found, the next step should involve diagnostic imaging. Duplex ultrasound with color flow is the non-invasive modality of choice. Findings suggestive of significant obstruction (Figure 1 ) include waveform dampening or monophasic changes, color aliasing suggestive of turbulent flow, and increased blood flow velocities at the suspected site(s) of stenosis. 12 In addition, ultrasound-based testing can also detect reversal of ipsilateral vertebral artery flow as seen in subclavian steal syndrome. Other more expensive and invasive tests include CT angiography (CTA) and/or magnetic resonance angiography. The latter provide excellent anatomical resolution with potential assessment of not only the subclavian artery but other supra-aortic vessels as well (Figure 2 ). Lastly, contrast angiography ( Figure 3 ) with invasive hemodynamic measurement of subclavian lesions can also confirm the diagnosis. Screening is especially important in patients awaiting coronary surgical revascularization. Those scheduled to undergo CABG with IMA grafting should have screening subclavian angiography when a > 10 mmHg bilateral arm blood pressure differential is found, if they have a history of radiation therapy to the chest, a history of vasculitis, or if they have known peripheral artery disease (including those who are asymptomatic with angiographic aortic or iliofemoral atheromatous disease found incidentally during initial coronary angiography).
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Treatment
Indications for treatment include disabling upper limb ischemia, including claudication, rest pain and digital embolization; vertebrobasilar insufficiency from steal syndrome; anginal symptoms from coronary steal via IMA graft; leg claudication in the setting of axillo-femoral grafts; and to increase flow before surgical procedures such as CABG using the IMA as an arterial conduit or creation of dialysis arteriovenous (AV) fistula. In a study by Patel et al., 14 indications for revascularization included arm ischemia (57%), vertebral-subclavian steal syndrome (37%), coronary-subclavian steal syndrome (21%), and planned coronary bypass surgery using the ipsilateral internal mammary artery (8%).
Potential modalities of treatment range from medical therapy alone, to surgical revascularization -with percutaneous interventions in the middle of the spectrum. Which therapeutic option is chosen depends on the patient and lesion characteristics.
Medical therapy
The evidence for the different treatment strategies of subclavian artery stenosis is exclusively observational and retrospective. There are no randomized clinical trials to compare the efficacy of one strategy versus another. While some argue for conservative management with medications, most agree that in the setting of symptoms, including subclavian steal (vertebral or coronary), claudication or ischemic sequelae, surgical or endovascular therapy is indicated. 15, 16 One single-center, retrospective study compared patients treated with endovascular intervention or medical therapy. 8 They analyzed data on 274 patients over a 14-year period with hemodynamically significant stenoses as assessed by angiography/catheterization or sonographic data. In this population, 165 were treated medically versus 109 with percutaneous transluminal angioplasty (PTA). Those with subclavian steal or severe claudication and ischemic symptoms were more likely to be intervened on, but a comparable number of less symptomatic patients (including some with steal) were treated medically. After a median follow-up of 42 months, they found a 60% reduction in hemodynamic subclavian artery stenosis as assessed by oscillography, Doppler and duplex sonography in the interventional cohort, but no significant difference in the number of patients with symptomatic disease at the time of follow-up between both groups. This study confirms that in the absence of symptoms or steal phenomena, patients should not be intervened on based on hemodynamic findings alone.
The applicability of the latter study in the current era of stents may be less robust, but one can argue that medical therapy has also improved significantly since 1998 (the last inclusion year). Today, aggressive medical therapy should include anti-platelet therapy (aspirin -or clopidogrel if intolerant of aspirin, particularly in those patients with concomitant coronary artery disease (CAD)), lipid-lowering therapy (i.e. statins) with a goal LDL of < 100 (option < 70), and blood pressure control (i.e. angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers). Those patients with diabetes would benefit from aggressive glycemic control (hemoglobin A1C goal of < 7), and tobacco smokers should be counseled to stop this behavior.
Surgical repair
Much of the literature regarding surgical repair of subclavian artery stenosis is encompassed in that reported under supraaortic trunk (SAT) stenoses, which includes brachiocephalic (or innominate), subclavian and common carotid artery interventions. The first surgical repair of a SAT was reported in 1951 by Shimizu and Sano. 17 Later, Diethrich et al. 18 and Crawford et al. 19 published data indicating that mortality could be reduced from 22% via a transthoracic approach to 5.6% using an extra-anatomic cervical repair technique. By 1999, mortality was reduced to 0.5% with stroke rates of less than 3.8% as reported by Berguer et al., 20 with patency rates of 91% and 82% at 5 and 10 years, respectively.
The various operations to correct subclavian stenosis include: axillary-axillary bypass, carotid-subclavian bypass, and transposition of the subclavian artery. Axillary-axillary bypass surgery has been shown to have good long-term results with several studies demonstrating prolonged symptom relief with durable bypass graft patency rates. 21, 22 At 56 months, Perkins et al. found 75% of 16 patients to be symptom-free with similar long-term graft patency rates. 21 Similarly, Chang et al. reported primary and secondary patency rates of 88% and 91%, respectively, at 10 years. 22 Carotid-subclavian operations also provide favorable outcomes. Several studies using this method of revascularization have shown low mortality (0.8%), low stroke rates (0.5-5%), and good mid-term and long-term patency rates (92% and 83% at 5 and 10 years, respectively). 19, [23] [24] [25] Less commonly used, with equally low mortality rates (< 1%) but higher patency rates (98% at 60 months per Cina et al.), is subclavian transposition.
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Endovascular interventions
Percutaneous transluminal angioplasty (PTA) was first reported in the 1970s after successful intravascular interventions were done in other medium-to-large arteries such as the coronaries, renal and lower extremity arteries. 28 By the 1980s, several reports of PTA of aortic arch vessels appeared in the literature. [29] [30] [31] While balloon dilation of these stenoses was shown to be efficacious and safe, the major issue was need for re-intervention as long-term patency was much inferior to surgical correction. Other issues with PTA included cerebral embolization via the ipsilateral vertebral artery during subclavian angioplasty, although in some cases the delayed reversal of vertebral flow after subclavian PTA described by Ringelstein and Zeumer 32 decreased this complication. Stenting and in certain cases distal embolic protection were later introduced to address some of these problems.
While rates of restenosis at 3 years are as high as 21% with PTA alone in some studies, 33 acute occlusion or thrombosis is rare (likely due to the large caliber of the vessels involved). As highlighted in Table 1 , pending the duration of follow-up, the primary restenosis rate is approximately 4.5-14.6% over a 3-year period. [34] [35] [36] As with angioplasty, acute or subacute thromboses with stents have not been reported in any of the above studies. One recent paper reported 10-year case series data from a single center of 110 patients undergoing endovascular repair of symptomatic subclavian artery stenosis (steal and severe claudication). 37 Stents were placed in 58% of patients with 93% technical and clinical success, and 1% stroke rate. The primary clinical patency at 5 years was 89%, with a median restenosis-free period of 2 years based on quarterly duplex scans.
The largest case series reported to date was published in 2008.
14 This study included 170 patients from 1993 to 2006 who underwent stenting of 177 subclavian or innominate arteries (94% and 6%, respectively). Technical success was reported in 174/177 arteries (98%), including 19/21 for total occlusions (90%). There were no procedural deaths and a major complication rate of 0.6% (one stroke occurred) and minor complication rate of 5.3% (including dissection, transient ischemic attack (TIA), distal emboli, thrombosis, hematoma or bleeding, and access site issues). Treated patients after an average of 3 years of follow-up, including 89% of the original patient cohort, remained asymptomatic. A primary patency rate of 83% and a secondary patency of 96% (after only 14% of patients required repeat target vessel revascularization at 3 years) out to 5 years of follow-up were noted. The authors attributed their success to improved techniques including recanalization via simultaneous femoral (antegrade) and brachial (retrograde) approaches (used in 62% of occlusions).
The technical success rate of percutaneous treatment for stenoses with stents has not been a significant issue, as exemplified in Figure 4 . As can be seen in the studies highlighted above, success rates ranging from 91% to 100% 3, 4, 36, 38, 39 have been reported in other case series. Equally important has been the success rate of treatment of total occlusions which has ranged from 83% to 94%. 14, 40, 41 Complication rates have also been minimal as periprocedural deaths have not been reported, and stroke rates (TIAs included) have ranged from 0.9% to 1.4%. 3, 4, 36, 38, 39 Major complications, including access site hematomas, distal embolization, and arm arterial thrombosis, have also been minimal. 3, 38 The latter statistical figures are better than those obtained by surgery and are cited as justification for the use of minimally invasive endovascular techniques for the treatment of subclavian artery stenosis.
Miscellaneous issues and follow-up
As with coronary arteries, long-term patency in stented subclavian arteries can be aided by the use of anti-platelet agents. Unfortunately, randomized data are lacking and guidelines for appropriate therapy post subclavian artery stenting have not been established. Given the large caliber of the artery, the reported incidence of stent thrombosis is rare. As such, patients undergoing subclavian artery stent placement may be treated with dual anti-platelet therapy for 1 month after the procedure (clopidogrel 75 mg daily, aspirin alone should be continued indefinitely in the presence of concomitant CAD). 14, 35 If subclavian stenosis is detected prior to CABG (i.e. gradient > 10-15 mmHg across the lesion) and an IMA conduit is planned, depending on the urgency of revascularization, treatment can be either surgical or endovascular. Typically, a free IMA graft or the contralateral in situ IMA if its subclavian (or innominate) is free of significant disease, are the recommended surgical options. 42 Free IMA grafts have been shown to be as safe and durable as in situ conduits, with an increased operating time being the only downside. As noted earlier, because definitive studies as to the duration of dual anti-platelet therapy after peripheral artery stenting are unavailable, it is difficult to say how long after subclavian stenting patients should wait before undergoing open heart surgery. Centers comfortable performing subclavian stenting on aspirin alone or CABG on thienopyridines may consider endovascular repair of subclavian lesions as first-line therapy, with open heart surgery shortly thereafter. 42 Otherwise, as done in coronary artery stenting with bare metal stents, a 4-week delay while on dual anti-platelet therapy can be observed.
Post-stenting follow-up should be done at 1, 6 and 12-month intervals initially and yearly thereafter. In addition to history and physical examination, with bilateral arm blood pressure measurements at each visit, a color Doppler ultrasound with velocity assessment should be performed with any concerning symptoms or a > 10 mmHg change in arm blood pressure difference. 43 
Conclusion
While there are direct and indirect benefits to diagnosing subclavian stenosis, it is a disease entity that is often overlooked in our patient population. Evidence exists to support the use of non-invasive screening tools with excellent negative predictive capabilities. Therefore, it is important that the vascular medicine practitioner be aware of the disease process, symptoms and exam findings, as well as treatment options for their patients. Medical therapy for atherosclerotic risk factors should be standard care for all patients with any degree of subclavian stenosis. When an intervention is indicated, a percutaneous approach is favored over surgical intervention in the current era of angioplasty and stenting. Subclavian stenting is characterized by proven efficacy and long-term patency, without the need for general anesthesia, requiring shorter healing times and length of hospital stay which can lead to significant cost savings per procedure. 44 In experienced hands and operators, intravascular treatment of symptomatic subclavian lesions can be achieved with near perfect technical success (98%), low complication rates (5.3%, only 0.6% stroke) and excellent long-term primary patency (85-90% at 3 years).
